The U.S. Food and Drug Administration (FDA) has approved a new formulation of the anticancer therapy nilotinib, branded Cavhanza, to treat certain people with chronic…
Blood cancer
Blood cancer is a broad term encompassing diseases in which blood cells grow too much or develop abnormally. Typically, blood cancers are classified into three main categories – leukemia, lymphoma, and myeloma – but they can be further divided into dozens of specific types, each with unique features.
A wide range of therapies are available for treating blood cancer, from chemotherapy and targeted therapy to radiation, stem cell transplant, and surgery. When devising a suitable treatment plan for blood cancer, healthcare providers take into account various factors, such as age, overall health, the specific type of blood cancer, and potential treatment side effects.
Latest news
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to STX-0712, an experimental therapy Solu Therapeutics is developing to treat chronic myelomonocytic…
The U.S. Food and Drug Administration (FDA) has approved a new combination therapy — Inqovi (decitabine and cedazuridine) plus Venclexta (venetoclax) — to treat adults…
A new genetic test for a group of blood cancers known as myeloid malignancies is expected to soon be available to certain people in…
The U.S. Food and Drug Administration (FDA) has named Terns Pharmaceuticals’ investigational oral agent TERN-701 a breakthrough therapy for potential use in certain people…
In adults newly diagnosed with a type of blood cancer called core-binding factor acute myeloid leukemia (CBF-AML), genetic mutations present before treatment do not…
